Pep-Dc1
Ovarian Carcinoma
Centre Hospitalier Universitaire VaudoisvaccinePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
244 Active assets in the Ovarian Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trabectedin AGO Research GmbH | Phase 4 | BBB |
Mirvetuximab Soravtansine AstraZeneca | Phase 3 | BBB |
Olaparib Imunon | Phase 4 | BB |
Irinotecan OHSU Knight Cancer Institute | Phase 2 | BB |
Carboplatin University of Washington | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →